3626 results for «295»

Filter By

3626 results

TAVI and mitral interventions

17 Feb 2019 – From PCR Tokyo Valves 2019

Consult this session to discover challenging TAVI and mitral interventions, such as: bioprosthetic valve fracture, concomitant off-pump beating heart mitral repair and LAA closure, annulus rupture immediately after balloon-expandable transcatheter heart valve implantation, and more!

TAVI and mitral interventions

Excellent abstracts from Japan

17 Feb 2019 – From PCR Tokyo Valves 2019

Consult this session in English and Japanese to learn more about various TAVI studies and cases, regarding topics such as comparison between self- and balloon- expandable valve, clinical outcomes of the 20mm SAPIEN 3, single proglide vascular preclose technique, and more!

Excellent abstracts from Japan

PCR Tokyo Valves 2019 Opening Ceremony

16 Feb 2019 – From PCR Tokyo Valves 2019

Consult this session to discover the slides of PCR Tokyo Valves 2019 Opening Ceremony, a course which is expanding to become the major Asian forum in valvular interventions.

PCR Tokyo Valves 2019 Opening Ceremony

Impact of intravascular imaging guidance on percutaneous coronary intervention of severely calcified lesions: The ECLIPSE trial

29 Mar 2025

Aaysha Cader provides her take on the ECLIPSE trial presented by Gregg W. Stone at ACC.25 in Chicago.

Author

Aaysha Cader
Impact of intravascular imaging guidance on percutaneous coronary intervention of severely calcified lesions: The ECLIPSE trial

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

04 Nov 2021

Panos Xaplanteris review the RADIANCE-HTN Study, presented by Ajay Kirtane, an international randomized, sham-controlled clinical trial evaluating the safety and efficacy of renal denervation (RDN) in a population of treatment-resistant hypertensive patients. 

Panagiotis Xaplanteris

Author

Panagiotis Xaplanteris
RADIANCE-HTN: TCT 2021

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!

17 Oct 2020

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Author

Hector Garcia
Live from TCT Connect 2020: PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB
Didn’t find what you were looking for?